Enliven Therapeutics Inc. (ELVN)
NASDAQ: ELVN
· Real-Time Price · USD
20.24
0.47 (2.38%)
At close: Aug 15, 2025, 3:59 PM
20.22
-0.10%
After-hours: Aug 15, 2025, 06:46 PM EDT
Enliven Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -25.34M | -28.54M | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M | -20.77M | -16.72M | -14.72M | 32.19M | -10.55M | -8.89M | -8.67M | -8.39M | -13.65M | -13.16M | -10.26M |
Depreciation & Amortization | 154K | 74K | 80K | 80K | 78K | 79K | 77K | 78K | 74K | 67K | 64K | 60K | 52K | 39K | 33K | 24K | 25K | 25K |
Stock-Based Compensation | 7.72M | 6.8M | 5.34M | 5.18M | 5.14M | 4.51M | 3.06M | 3.4M | 4.2M | 2.26M | 735K | 1.1M | 701K | 654K | 617K | 1M | 917K | 947K |
Other Working Capital | n/a | -2.72M | -833K | 5.05M | -2.78M | -6.79M | 6.42M | 4.75M | 1.42M | -8.94M | 902K | -153K | 420K | -828K | 667K | 1.85M | 2.2M | -4.82M |
Other Non-Cash Items | 400K | 40K | 1.07M | 655K | -1.32M | -582K | 2.46M | -1.76M | -831K | 1.9M | -34.53M | 20K | 30K | 1.63M | 1.2M | 1.22M | 1.37M | 22K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -4.17M | n/a | n/a | -1.9M | -620.8K | 1.72M | -30K | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | -2.5M | -510K | 5.05M | -4.38M | -4.63M | 5.46M | 3.15M | 1.23M | -8.45M | 282K | 1.21M | 1.01M | -2.38M | 1.15M | 1.7M | 1.82M | -3.79M |
Operating Cash Flow | -17.06M | -24.13M | -17.2M | -12.19M | -20.43M | -23.36M | -12.48M | -15.89M | -12.05M | -20.84M | -1.88M | -6.45M | -7.12M | -10.36M | -6.59M | -10.9M | -10.37M | -13.02M |
Capital Expenditures | -139K | -20K | n/a | -22K | -2K | -20K | -14K | -16K | -88K | -31K | -101K | -14K | -303K | -194K | -57K | n/a | n/a | -12K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -40M | n/a | n/a | 35M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -240.19M | -59.23M | -116.52M | -234.22M | -120.83M | -56.78M | -41.3M | -75.53M | -151.43M | n/a | -35M | n/a | n/a | n/a | -17.79M | -22.23M | -3.81M | -3.72M |
Sales Maturities Of Investments | 56.74M | 60.67M | 117.24M | 196.67M | 77.17M | 38.91M | 80M | 40M | n/a | n/a | 6.82M | 23.11M | 6.48M | 5.47M | 3.3M | 13.4M | 7.2M | 22.04M |
Other Investing Acitivies | n/a | n/a | n/a | 52.4M | 10M | n/a | n/a | 40M | -151.43K | n/a | 35.1M | -23.11M | -6.48M | -5.47M | n/a | n/a | n/a | n/a |
Investing Cash Flow | -183.59M | 1.43M | 727K | 14.83M | -33.66M | -17.89M | 38.69M | -35.55M | -151.52M | -31K | 41.82M | -14K | -303K | -194K | -57K | -8.83M | 3.39M | 18.3M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 218.38M | n/a | 90.48M | n/a | n/a | 270K | n/a | n/a | -2.82M | 237.44M | -2.38M | 164K | 5K | 409K | -1.48M | n/a | n/a | n/a |
Financial Cash Flow | 218.38M | 234K | 39.97M | 1.12M | 1.81M | 90.27M | 90K | -425K | -2.82M | 237.44M | -1.23M | 164K | 5K | 409K | -1.48M | 46.99M | 1.66M | 460K |
Net Cash Flow | 17.73M | -22.47M | 23.5M | 3.75M | -52.29M | 49.02M | 26.35M | -51.87M | -166.39M | 216.57M | 38.71M | -6.3M | -7.42M | -10.15M | -8.13M | 27.08M | -5.49M | 5.66M |
Free Cash Flow | -17.2M | -24.15M | -17.2M | -12.21M | -20.44M | -23.38M | -12.5M | -15.91M | -12.14M | -20.88M | -1.98M | -6.46M | -7.43M | -10.55M | -6.65M | -10.9M | -10.37M | -13.03M |